Biofrontera (BFRI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues reached $9.0M, up 1.5% year-over-year, with nine-month revenues at $24.8M, a 5.6% increase, both impacted by Hurricane Milton shipment delays; Ameluz achieved record volume in September and RhodoLED XL launch contributed to growth.

• Net loss for Q3 2024 was $5.7M, improved from $6.3M in Q3 2023; nine-month net loss was $16.4M, down from $23.7M prior year.

• FDA approved increased Ameluz dosage per treatment in October 2024, supporting larger field treatments and future label expansion.

• Company transferred all clinical trial activities for Ameluz in the U.S., improving profitability and control over development.

• Xepi product line classified as held for sale, with sale expected within 6–12 months as part of strategic review.

Financial highlights

• Product revenue for Q3 2024 was $9.0M; nine-month product revenue was $24.8M, both reflecting higher Ameluz pricing and RhodoLED XL launch, offset by shipment delays.

• Adjusted EBITDA for Q3 was -$4.6M, down from -$3.9M in Q3 2023, mainly due to higher R&D costs; nine-month Adjusted EBITDA improved to -$13.9M from -$15.8M.

• Cash and equivalents at September 30, 2024, were $2.9M, up from $1.3M at year-end 2023.

• SG&A expenses reduced by 14% in the first nine months year-over-year.

• Cost of revenue for nine months increased to $13.3M from $12.1M year-over-year.

Outlook and guidance

• Revenue growth for 2024 expected in the mid- to high teens percentage, similar to prior years.

• Cash flow break-even targeted for late 2025 into 2026.

• Q4 anticipated to be strong due to seasonality, price increase, and delayed Q3 shipments.

• FDA filing for Ameluz in sBCC expected in H1 2025, with potential approval in early 2026.

• Management plans to expand Ameluz commercialization, control expenses, and seek additional capital to address going concern risks.